Introduction
============

Colorectal cancer (CRC) is the third most common cancer in Korea and its incidence rate has increased seriously every year [@B1], [@B2]. Previous studies demonstrated that colorectal neoplasms result from the sequential accumulation of gene alterations [@B3]-[@B5]. As a result, it is accepted that the adenoma-carcinoma sequence underlies the colorectal carcinogenesis via two distinct pathways, the chromosomal instability (CIN) pathway and microsatellite instability (MSI) [@B3]-[@B7]. Serrated polyps are histologically classified into hyperplastic polyp, traditional serrated adenoma, sessile serrated adenoma (SSA), and mixed hyperplastic/adenomatous polyp [@B8]. Though, SSAs have been considered to be nonneoplastic lesions without malignant potential, recent studies showed that SSAs may be the precursor of CRC with MSI [@B9]-[@B13]. This serrated neoplastic pathway is characterized by frequent *BRAF* mutation and infrequent *KRAS* mutation [@B14], [@B15].

The phosphoinositide-3-kinase, catalytic, alpha polypeptide (PIK3CA) gene encodes the catalytic subunit p110 alpha of phosphatidylinositol 3-kinase (PI3K) belonging to class 1A of PI3Ks. PIK3CA mutation promotes cell growth by stimulating AKT pathway in various cancers and has been reported in 10-30% of colorectal cancers [@B16]-[@B18]. PIK3CA amplification is found more frequently than PIK3CA mutation in various cancers and it promotes another mechanism for PI3K.AKT pathway [@B19]-[@B21]. In CRC, PIK3CA amplification was found in 38% of cancers and 25% of adenomas, suggesting its important role in the adenoma-carcinoma transformation model [@B22]. Furthermore, their results demonstrated that it may be an independent prognostic marker for better survival. However, the role of PIK3CA amplification in colorectal carcinogenesis has not been studied using colorectal precancerous legions.

In present study, PIK3CA amplification was investigated in colorectal precursor lesions, comprising of TAs and SSAs. To contribute to better understanding on colorectal carcinogenesis, *KRAS* and *BRAF* mutations key markers in CRCs, were also studied in these lesions. Clinicopathological characteristics in these patients were analyzed according to their genetic status.

Materials and Methods
=====================

Patients and DNA Extraction
---------------------------

For this study, the records of colonoscopic polypectomy performed at Dongsan Medical Center between 1999 and 2003 were reviewed and 64 TAs and 32 SSAs were selected. Exclusion criteria were: previous history of surgical resection for CRCs, and evidence of hereditary non-polyposis colorectal cancer (Amsterdam criteria) or familial adenomatous polyposis. Tumor area and adjacent normal mucosa were selected from slide according to hematoxylin and eosin stained sections. Subsequently, the selected areas from paraffin embedded tissues were used for DNA extraction. DNA was isolated by using DNA extraction Kit (Absolute^TM^ DNA extraction Kit, BioSewoom, Korea) according to the manufacturer\'s instructions.

PIK3CA Amplification
--------------------

Copy number of PIK3CA gene was analyzed by quantitative real-time (qRT) PCR. For the quantitative determination of PIK3CA content relative to nDNA, primers for specific amplification of exon 20 in PIK3CA gene and nDNA-encoded ß-actin gene were selected according to previous study [@B21]. Real-time PCR was then carried out on an LightCycler 480 II system (Roche Diagnostics, Germany) with a total volume of 20 µl reaction mixture containing 10 µl SYBR Green Master MIX (Takara, Japan), 8 pmol of each primers, and DNA (50 ng). The PCR conditions were 95°C for 1 min, followed by 40 cycles of 95°C for 15 s, and 60°C for 30 s. The threshold cycle number (Ct) values of the ß -actin gene and PIK3CA gene were determined. The copy number of PIK3CA in each tested specimen was then normalized against that of ß -actin gene to calculate the relative PIK3CA copy number. Each measurement was repeated in triplicate and 5 serially diluted control samples were included in each experiment. Copy amplification of PIK3CA gene was defined by a copy number ≥ 3. Samples with a PIK3CA/ ß -actin ratio between 1.0 and 3.0 were classified as having PIK3CA gain.

Microsatellite instability (MSI)
--------------------------------

MSI was analyzed with two microsatellite markers, BAT25 and BAT 26 based on previous studies demonstrated that these analyses can accurately detect MSI without the need for additional markers. Briefly, polymerase chain reaction (PCR) was performed using a thermal cycler (Applied Biosystems, USA). The PCR products were also denatured in formamide loading buffer (95% formamide, 20 mmol EDTA, 10 mmol NaOH, 0.05% bromophenol blue, 0.05% xylene cyanol) and electrophoresed through 7.5% and 10% polyacrylamide gels. Silver stain was performed to develop bands. MSI was defined as either a band shift or the appearance of a novel band in DNA from precancerous lesions. All experiments were repeated at least twice to rule out any artifacts. Direct DNA sequencing was performed on those PCR products that showed altered band mobility in the above analysis using the ABI 3730 DNA sequencer (Bionics Inc, Korea).

KRAS and BRAF Mutations
-----------------------

*KRAS* mutations in codons 12 and 13, and *BRAF* V600E mutation were analyzed by pyrosequencing (PyroMark Q24, Sweden). Primers for amplification and pyrosequencing were designed as previously described [@B23]. The pyrosequencing reaction was performed on a PyroMark Q24 instrument using the Pyro Gold Q24 Reagents (Qiagen, Netherlands). The pyrosequencing primers were used in a final concentration of 0.3 µmol/L. Resulting data were analyzed and quantified with the PyroMark Q24 software version 2.0.6 (Qiagen, Netherlands).

Statistical Analysis
--------------------

SPSS software for Windows was used. Statistical comparisons for significance were made with Wilcoxon signed-rank test for paired samples. Chi-square, Fischer\' exact tests and Mann Whitney U test were used to analyze the relationship between variables. A p value \< 0.05 was considered statistically significant.

Result
======

Precursors of CRCs were comprised of 64 tubular adenomas (TAs) and 32 sessile serrated adenomas (SSAs). Clinicopathological characteristics of TAs and SSAs were presented in Table [1](#T1){ref-type="table"}. Higher frequency of KRAS mutation was found in TA than that in SSAs (*p*= 0.012). However, BRAF mutation was shown only SSAs (*p*\< 0.001), therefore, *KRAS* and *BRAF* mutations were mutually exclusive in TAs and SSAs. Other clinicopathological characteristics were not associated with KRAS and BRAF mutations. Using real-time PCR methods, the expression level of PIK3CA gene were analyzed in paired TAs and SSAs. The average of PIK3CA expression level between tumors and normal tissues was not significantly different in both TAs and SSAs (Figure [1](#F1){ref-type="fig"}). In normal and tumor tissues, higher expression of PIK3CA gene was found in TAs than SSAs (*p* \< 0.05). With a gene copy number of 3 or more defined as amplification, we found the incidence of PIK3CA amplification in colorectal precancerous legions was 19.8% (19/96) in the present study (Table [2](#T2){ref-type="table"}). Higher frequency of PIK3CA amplification was found in TAs (25.0%, 16/64) than SSAs (9.4%, 3/32), however, it did not reach statistical significance (*p* = 0.07). Similar frequency of PIK3CA gain was found in TAs and SSAs. Clinicopathological characteristics of PIK3CA amplification was presented in Table [3](#T3){ref-type="table"}. In TAs, PIK3CA amplification was associated with left-side (*p* = 0.025). And mutual exclusivity between PIK3CA amplification and KRAS mutation was found in TAs, though it did not get to statistical significance (*p* = 0.06). In SSAs, PIK3CA amplification did not have any clinical significance.

Discussion
==========

This article demonstrates that PIK3CA amplification is important and early event in colorectal precancerous legions, especially in TAs. PIK3CA amplification was found in 19.8% (19/96) of precancerous legions and this result was in agreement with previous studies [@B19], [@B21], [@B23]-[@B27]. PIK3CA amplification has been reported in 30% of ovarian cancer, 33.1% of lung squamous cell carcinomas, 32.3% of head and neck squamous cell carcinomas, 12.2% of endometrial carcinomas, 37.9% of CRC, 15% of anaplastic thyroid cancer, and 67% of gastric cancer. Jehan et al. [@B22] showed that PIK3CA amplification was observed in 25.0% of colorectal adenomas and CRCs with PIK3CA amplification is an independent prognostic marker for better survival. So, we studied clinicopathological characteristics of PIK3CA amplification in precancerous legions, comprising of TAs and SSAs. Higher frequency of PIK3CA amplification was found in TAs more than SSAs, though it did not reach statistical significance. In SSAs, PIK3CA amplification was not associated with any clinicopatholotical characteristics, however, PIK3CA amplification had various significance in TAs. Higher frequency of PIK3CA amplification was found in left-side TAs and KRAS wild type. It indicates that PIK3CA amplification may play an important role in the development of left-side TA independently with KRAS mutation. In many cancers, PIK3CA amplification was associated with poor prognosis and cancer development, by activating the PI3K/Akt signaling pathway aberrantly. Thus, specific genotype-based targeting against the PI3K/Akt signaling pathway may be an effective therapeutic strategy for TAs. Its molecular mechanisms should be studied further to clarify its classification.

Mutual exclusivity between PIK3CA amplification and KRAS mutation was introduced firstly in previous study by Konopka et al. [@B24]. It has been reported inverse relationship between PIK3CA amplification and PIK3CA mutation in various cancers [@B19], [@B21]. Previous study indicated that PIK3CA mutation may play important role in benign and early stage of colorectal neoplasm [@B28]. We studied PIK3CA mutation in 20 patients with TAs, as a preliminary study, however, PIK3CA mutation was not found (data not shown). Therefore, we did not include the analysis of PIK3CA mutation in present study. Previous studies also demonstrated rare PIK3CA mutation in Korean populations with CRCs [@B29], [@B30]. Besides the ethnic factor, the absence of PIK3CA mutation might be affected by the morphology of the adenoma. Chang, Chiu [@B31] demonstrated that the frequency of the PIK3CA mutation was lower in non-polypoid colorectal neoplasm; however, we had no record of the morphology of colorectal lesion. Nevertheless, these data and our result indicated that PIK3CA amplification is more important factor than PIK3CA mutation in colorectal carcinogenesis.

Taken together, we studied the PIK3CA amplification in colorectal precancerous legions for the first time and analyzed their clinicopathological significance. For the first time, a possible role of PIK3CA amplification in development of CRC is suggested, and it may drive the development of left-side TAs independently with *KRAS* mutation. This finding may have an important implication for the treatment and the prevention of CRCs.

![PIK3CA expression level in TAs and SSAs. No significant difference between normal and tumor samples was found in both TAs and SPs. Higher PIK3CA amplification was observed in normal and tumor samples of TAs than SSAs.](ijmsv12p0349g001){#F1}

###### 

Clinicopathological characteristics of TAs and SSAs in present study

                        TA (n = 64, %)   SSA (n = 32, %)   p
  --------------------- ---------------- ----------------- --------------
  **Age (mean ± SD)**   60.36 ± 10.57    59.03 ± 9.56      0.412
  **Sex**                                                  0.877
  Male                  43 (67.2)        22 (68.8)         
  Female                21 (32.8)        10 (31.2)         
  **Region**                                               0.51
  Proximal              18 (28.1)        7 (21.9)          
  Distal                46 (71.9)        25 (78.1)         
  **MSI**                                                  1.00
  (+)                   7 (10.9)         4 (12.5)          
  (-)                   57 (89.1)        28 (87.5)         
  **Kras mutation**                                        **0.012**
  (+)                   15 (23.4)        1 (3.1)           
  (-)                   49 (76.6)        31 (96.9)         
  **Braf mutation**                                        **\< 0.001**
  (+)                   0 (0)            6 (18.8)          
  (-)                   64 (100)         26 (81.2)         

###### 

Prevalence of PIK3CA content changes in TAs and SSAs

              Total   Gain (N, %)   Amplification (N, %)
  ----------- ------- ------------- ----------------------
  **TAs**     64      19 (29.7)     16 (25.0)
  **SSAs**    32      11 (34.4)     3 (9.4)
  **Total**   96      30 (31.2)     19 (19.8)

###### 

Clinicopathological characteristics of PIK3CA amplification in TAs and SSAs

                      TA (n = 64)     p           SSA (n = 32)   p
  ------------------- --------------- ----------- -------------- ------
  **Total^\*^**       25.0% (16/64)               9.4% (3/32)    
  **Sex**                             0.28                       0.22
  Male                20.9% (9/43)                13.6% (3/22)   
  Female              33.3% (7/21)                0% (0/10)      
  **Side**                            **0.025**                  0.34
  Right               5.6% (1/18)                 0% (0/7)       
  Left                32.6% (15/46)               12.0% (3/25)   
  **MSI**                             1.00                       1.00
  (+)                 28.6% (2/7)                 0% (0/4)       
  (-)                 24.6% (14/57)               10.7% (3/28)   
  **KRAS mutation**                   0.06                       0.74
  (+)                 6.7% (1/15)                 0% (0/1)       
  (-)                 30.6% (15/49)               9.7% (3/31)    
  **BRAF mutation**                   \-                         0.50
  (+)                 \-                          16.7% (1/6)    
  (-)                 25.0% (16/64)               7.7% (2/26)    

^\*^*p*= 0.07 between TA and SSA
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